THERAPEUTIC SLTNS INTL - TSOI STOCK NEWS

Therapeutic Solutions International (OTC Markets: TSOI) announced the addition of stem cell expert Francisco Silva to its Scientific Advisory Board. Silva, a leader in clinical stem cell development, currently serves as Vice President of Research and Development at BioRestorative Therapies. His expertise is expected to enhance TSOI's therapeutic pipeline, particularly in regenerative medicine and COVID-19 treatments. TSOI is in discussions for partnerships to develop its JadiCell™ technology, which has shown high efficacy in clinical trials for COVID-19 patients.

Therapeutic Solutions International (OTC Markets: TSOI) announced promising preclinical results using JadiCells™ for treating COPD. In animal studies, JadiCells™ significantly reduced lung damage compared to traditional stem cells and enhanced anti-inflammatory responses. The company is pursuing further exploration of these cells, considering a new IND application. Following successful outcomes in treating COVID-19 patients, TSOI aims to fortify its intellectual property while identifying optimal indications for JadiCells™ development.

Therapeutic Solutions International (OTC: TSOI) announced that Dr. Peter C. Farrell joined the Advisory Board of its spin-off, Campbell Neurosciences, focused on suicide as a biological disorder. The company reported promising results from its Campbell Score® blood test, which predicts suicidal ideation. Dr. Farrell, an established leader in medical technology, is expected to enhance the company's strategic direction. Campbell, previously a division of Therapeutic Solutions, is now an independent biotech poised for growth in the mental health domain.

Therapeutic Solutions International, Inc. (OTC Markets: TSOI) has appointed Dr. Boris Reznik to its Advisory Board to enhance the FDA-cleared Phase III JadiCell™ COVID-19 clinical trial. Dr. Reznik brings extensive experience in drug and device development, having successfully contributed to various biotech ventures. The clinical trial results for JadiCell™ show a 100% survival rate for COVID-19 patients under 85 and 91% for those over 85. This recruitment aims to leverage Dr. Reznik's expertise to optimize value in ongoing therapeutic developments.

Therapeutic Solutions International (OTC Markets: TSOI) announced a patent application revealing a novel mechanism of action for its JadiCell™ universal donor stem cell in treating advanced lung inflammation, akin to Delta Variant infection. Research indicated that JadiCell™ administration increased CD73 expressing T cells, crucial for its efficacy. Additionally, low-dose interleukin-2 enhanced JadiCell™'s protective effect against lung inflammation. The company's strategy emphasizes understanding therapeutic mechanisms, potentially leading to strategic partnerships and commercialization opportunities.

Therapeutic Solutions International (OTC: TSOI) has initiated preparations for an Emergency Use Authorization (EUA) to the FDA for its JadiCells™ therapy aimed at treating lung injuries related to COVID-19. The EUA enables the use of unapproved medical products during public health emergencies. The company reports promising preclinical data and recently received FDA clearance for a Phase III trial, where JadiCells™ showed 100% efficacy in saving lives of COVID-19 ICU patients below 85. Experts from its advisory board are facilitating fast-track approval processes.

Therapeutic Solutions International, Inc. (TSOI) announced significant findings regarding its JadiCell™ adult stem cells, indicating their superior capacity to promote neurogenesis compared to other stem cell types in inflammatory conditions. The research, linked to potential COVID-19 treatments, showed JadiCells were effective in stimulating brain cell production while other stem cells were not. Notably, in a clinical trial, JadiCell™ demonstrated a 100% survival rate for COVID-19 patients under 85 years. The company is advancing toward Phase I/II and Phase III trials for CTE and COVID-19 treatments, respectively.

Therapeutic Solutions International (OTC: TSOI) has completed FDA-requested preclinical experiments to initiate Phase I/II clinical trials for JadiCell™ treatment of chronic traumatic encephalopathy (CTE). This marks a significant milestone as TSOI holds the sole Investigational New Drug application for CTE. The FDA's acceptance of their CTE definition for living patients is viewed as a breakthrough. TSOI aims to leverage insights from ongoing COVID-19 trials to enhance treatment for CTE, addressing a critical medical need for athletes and military veterans.

Therapeutic Solutions International (OTC: TSOI) received FDA clearance for a Phase III trial of JadiCell™, a universal donor stem cell treatment for COVID-19 related lung failure. Previous studies indicate JadiCell™'s effectiveness, showing 100% survival in patients under 85 and 91% in those over 85. This FDA approval marks a pivotal step toward market registration, positioning TSOI uniquely in the treatment of severe COVID-19 cases. Company leadership expresses confidence in JadiCell™'s potential in addressing the ongoing pandemic and plans to expand research into related conditions.